Also, we observed the activation of the NRE2 pathway in NFE2L2-mutated PDX samples in squamous cell lung cancer (LUSC), suggesting that PDXs may be suitable for studying key oncogenic pathways and corresponding drug responses. This evidence concerns the gene NFE2L2 and squamous cell lung carcinoma.